CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
stereotactic radiosurgery +2 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00458484
NCT00458484N/ACompleted
CompareCT.gov

Evaluation of a Radio-Surgical Approach for the Treatment of Kidney Tumors in Poor Surgical Candidates

Case Comprehensive Cancer Center·interventional·Posted Apr 11, 2007·Updated Jul 22, 2020

In Brief

A clinical study evaluating stereotactic radiosurgery, Renal Biopsy, and 1 other intervention for Kidney Cancer. Completed, enrolled 31 participants across 3 sites.

Detailed Summary

RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial studies the side effects and best dose of giving stereotactic radiosurgery and to see how well it works in treating patients with kidney tumors who are poor candidates for surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 11, 2007
Enrollment StartFeb 20, 2007
Primary CompletionMar 12, 2017
Study CompletionSep 12, 2019
TodayJul 2, 2026
Enrollment to primary: 10.1 yearsPosted 19.2 years ago

Interventions

stereotactic radiosurgeryradiation

Series I: Radiation will be delivered in 4 fractions. Series II: Radiation will be delivered in 3 fractions.

Renal Biopsyprocedure

At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.

Serum Blood Markersprocedure

ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.